Addressing unmet clinical needs in treatment-resistant breast cancer: expanding the diagnostic–prognostic landscape through next-generation inflammatory signatures
- 1Department of Biomedical and Laboratory Science, Division of Haematology, Africa University , ,
Abstract
Treatment-resistant breast cancer remains a major clinical challenge because conventional clinicopathological and molecular biomarkers incompletely capture the dynamic interactions between tumour cells, immunity, inflammation, and the systemic host response. Next-generation inflammatory signatures offer an opportunity to expand the diagnostic–prognostic landscape by integrating cellular, molecular, immune, and thromboinflammatory indicators with established tumour characteristics. This narrative review critically examines emerging evidence for neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, C-reactive protein, cytokines, tumour-associated macrophages, myeloid-derived suppressor cells, neutrophil extracellular traps, coagulation biomarkers, and liquid-biopsy-derived measures in treatment-resistant breast cancer. Particular attention is given to sources of heterogeneity, including population characteristics, tumour subtype, treatment exposure, comorbid inflammation, sampling time, specimen processing, analytical platforms, and inconsistent biomarker thresholds. The review further evaluates the transition from biomarker discovery to clinical decision support, highlighting the need for prospective multicentre validation, standardised analytical procedures, external validation of computational models, and integration with molecular subtyping, circulating tumour DNA, imaging, and immune profiling. Rather than interpreting inflammation as a static prognostic variable, longitudinal inflammatory trajectories may provide earlier signals of biological treatment resistance and complement conventional measures of disease progression. Future research should establish clinically actionable inflammatory combinations and evaluate biomarker-guided anti-inflammatory strategies alongside standard therapies. Ultimately, integrating inflammatory phenotypes with tumour molecular characteristics may facilitate earlier recognition of resistance and more precise, dynamic, and equitable breast cancer management.
Related
- Blood-based inflammatory biomarkers in ovarian cancer: addressing the challenge of early detection, metastasis, and prognostic stratification.
- Integrative Multi-omics and machine learning analysis of sphingolipid-associated molecular stratification identifies diagnostic and prognostic signatures in idiopathic pulmonary fibrosis
- Generative AI for Synthetic Medical Image Generation in Oncology: Addressing Data Scarcity in AI-Driven Cancer Diagnosis
- Survival modeling and assessing prognostic factors of colorectal cancer in Ethiopia: Addressing violation of statistical assumptions
- Platform-agnostic quantification for molecular interception of oral and esophageal malignancies: a global study addressing the diagnostic divide
BibTeX
@article{obeagu2026addressing,
title = {{Addressing unmet clinical needs in treatment-resistant breast cancer: expanding the diagnostic–prognostic landscape through next-generation inflammatory signatures}},
author = {Emmanuel Ifeanyi Obeagu},
journal = {Oncology reviews},
year = {2026},
month = oct,
doi = {10.3389/or.2026.1918787},
url = {https://europepmc.org/article/PMC/PMC13719874},
note = {CC BY},
}
RIS
TY - JOUR
TI - Addressing unmet clinical needs in treatment-resistant breast cancer: expanding the diagnostic–prognostic landscape through next-generation inflammatory signatures
AU - Emmanuel Ifeanyi Obeagu
PY - 2026
DA - 2026/10/16
JO - Oncology reviews
DO - 10.3389/or.2026.1918787
UR - https://europepmc.org/article/PMC/PMC13719874
AB - Treatment-resistant breast cancer remains a major clinical challenge because conventional clinicopathological and molecular biomarkers incompletely capture the dynamic interactions between tumour cells, immunity, inflammation, and the systemic host response. Next-generation inflammatory signatures offer an opportunity to expand the diagnostic–prognostic landscape by integrating cellular, molecular, immune, and thromboinflammatory indicators with established tumour characteristics. This narrative review critically examines emerging evidence for neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, C-reactive protein, cytokines, tumour-associated macrophages, myeloid-derived suppressor cells, neutrophil extracellular traps, coagulation biomarkers, and liquid-biopsy-derived measures in treatment-resistant breast cancer. Particular attention is given to sources of heterogeneity, including population characteristics, tumour subtype, treatment exposure, comorbid inflammation, sampling time, specimen processing, analytical platforms, and inconsistent biomarker thresholds. The review further evaluates the transition from biomarker discovery to clinical decision support, highlighting the need for prospective multicentre validation, standardised analytical procedures, external validation of computational models, and integration with molecular subtyping, circulating tumour DNA, imaging, and immune profiling. Rather than interpreting inflammation as a static prognostic variable, longitudinal inflammatory trajectories may provide earlier signals of biological treatment resistance and complement conventional measures of disease progression. Future research should establish clinically actionable inflammatory combinations and evaluate biomarker-guided anti-inflammatory strategies alongside standard therapies. Ultimately, integrating inflammatory phenotypes with tumour molecular characteristics may facilitate earlier recognition of resistance and more precise, dynamic, and equitable breast cancer management.
SN - 1970-5565
SN - 1970-5557
ER -